AAPL 200.275 3.6835% MSFT 366.73 2.1191% NVDA 98.7901 1.94% GOOGL 151.18 2.3769% GOOG 153.648 2.5277% AMZN 173.255 3.5471% META 499.7028 3.1038% AVGO 169.28 1.8471% LLY 825.56 0.9217% TSLA 238.2263 4.7149% TSM 151.7625 2.6393% V 331.98 3.7113% JPM 235.695 2.9281% UNH 424.8971 -0.1018% NVO 59.54 2.0744% WMT 94.87 2.662% LVMUY 111.52 2.5943% XOM 108.17 2.6768% LVMHF 558.93 2.6728% MA 527.65 3.5989%
AAPL 200.275 3.6835% MSFT 366.73 2.1191% NVDA 98.7901 1.94% GOOGL 151.18 2.3769% GOOG 153.648 2.5277% AMZN 173.255 3.5471% META 499.7028 3.1038% AVGO 169.28 1.8471% LLY 825.56 0.9217% TSLA 238.2263 4.7149% TSM 151.7625 2.6393% V 331.98 3.7113% JPM 235.695 2.9281% UNH 424.8971 -0.1018% NVO 59.54 2.0744% WMT 94.87 2.662% LVMUY 111.52 2.5943% XOM 108.17 2.6768% LVMHF 558.93 2.6728% MA 527.65 3.5989%

mid-cap

Technical Analysis on One NASDAQ- Listed Health Technology Stock- VKTX

Jan 31, 2025 | Team Kalkine
Technical Analysis on One NASDAQ- Listed Health Technology Stock- VKTX
Image source: shutterstock

VKTX:NASDAQ
Investment Type
Mid - Cap
Risk Level
Action
Rec. Price (US$)

Viking Therapeutics, Inc. (NASDAQ: VKTX)                                                                       

Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders.

 

Technical Observation (on the daily chart): 

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.